Biolevate, a Paris-based startup, has secured €6 million in Seed funding to accelerate medical writing in the pharmaceutical industry. The company's platform leverages NLP and computer vision to streamline the creation of research and compliance documents.
CEO Joel Belafa and COO Nathan Chen, driven by their shared frustration with the slow pace of R&D and market access for therapeutic products, developed the initial prototype, Elise. They later brought on CTO Anas Laaroussi and CPO Antoine De Torcy.
The platform acts as an AI assistant for medical writers, guiding them through materials and reducing the time needed to understand and correct the system. This addresses the administrative burden on pharma companies in creating regulatory documentation.
Biolevate's technology aims to improve the efficiency of medical writing, a labor-intensive process often hindered by a lack of software and expert writers. This is especially relevant given the increasing pace of drug development aided by AI.
EQT Ventures led the funding round, recognizing the potential of AI in transforming medical documentation. Biolevate was also recently featured on Station F's Future 40 list.
If the current strategy doesn't succeed, Biolevate plans to offer its platform as a service to other industries, sell its models as an API, or provide drug discovery professional services. For related information, see articles on Volta's funding round, IMAX's use of AI, and ServiceTitan's IPO.